Home / M&A Activity / White Oak Merger Forms Big Data Firm; LaMontagne Named CEO

White Oak Merger Forms Big Data Firm; LaMontagne Named CEO

Arlington Capital Partners has merged its portfolio company White Oak Technologies Inc. with FGM Inc. to create Novetta Solutions, the private equity firm announced Wednesday.

Peter LaMontagne, former president and CEO of Paradigm Holdings, will serve as Novetta’s CEO.

He has led CACI International Inc.’s (NYSE: CACI) cyber practice and served as a senior vice president at ManTech International Corp. (NASDAQ: MANT).

The newly-created company will work with big data and provide technology solutions to the intelligence and defense communities.

The company’s 350 employees will provide services in areas involving information exploitation, cybersecurity, cloud computing and solution engineering.

White Oak CEO Alan Broder said the merger combines FGM’s data analytics and information sharing offerings with White Oak’s software and big data offerings.

Michael Lustbader, a partner at Arlington Capital, said the company plans to provide additional capital to support Novetta’s growth plans.

Senior management from FGM and White Oak will hold leadership positions at the new company, including:

  • Alan Broder, chairman and fellow
  • Scott Gessay, president
  • Kris Heim, chief technology officer
  • Larry Chang, senior vice president of operations
  • Mike Fox, senior vice president of corporate business development and chief strategy officer.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.